Skip to main content
Premium Trial:

Request an Annual Quote

DiaDexus Funds Michigan s Hanash in Biomarker Research Deal

NEW YORK, Sept. 4-DiaDexus will support University of Michigan geneticist Samir Hanash in research using proteomic techniques to develop new biomarkers to diagnose and treat cancer, the company said today.


DiaDexus will provide research funding in exchange for exclusive licensing rights to discoveries of commercial interest. The University of Michigan also stands to receive milestone and royalty payments on any products developed out of the collaboration.

 

Hanash's research will focus on identifying cell surface membrane proteins as potential therapeutic targets or biomarkers. His team will analyze normal and cancerous biological samples and cell lines with a sensitive technique.

 

DiaDexus did not disclose the financial terms of the arrangement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.